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Abstract: Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance
(MDR) and the complexity of the patients affected by these serious infections. As new antibiotic
therapies come on the market, limited data exist about the effectiveness of such treatments in clinical
practice. In this comparative effectiveness study of ceftolozane/tazobactam versus aminoglycoside- or
polymyxin-based therapies among hospitalized patients with positive MDR P. aeruginosa cultures, we
identified 57 patients treated with ceftolozane/tazobactam compared with 155 patients treated with
aminoglycoside- or polymyxin-based regimens. Patients treated with ceftolozane/tazobactam were
younger (mean age 67.5 vs. 71.1, p = 0.03) and had a higher comorbidity burden prior to hospitalization
(median Charlson 5 vs. 3, p = 0.01) as well as higher rates of spinal cord injury (38.6% vs. 21.9%,
p = 0.02) and P. aeruginosa-positive bone/joint cultures (12.3% vs. 0.7%, p < 0.0001). Inpatient mortality
was significantly lower in the ceftolozane/tazobactam group compared with aminoglycosides or
polymyxins (15.8% vs. 27.7%, adjusted odds ratio 0.39, 95% confidence interval 0.16–0.93). There were
no significant differences observed for the other outcomes assessed. In hospitalized patients with MDR
P. aeruginosa, inpatient mortality was 61% lower among patients treated with ceftolozane/tazobactam
compared to those treated with aminoglycoside- or polymyxin-based regimens.
Keywords: aminoglycosides; ceftolozane/tazobactam; comparative effectiveness; multi-drug resistant;
polymyxins; Pseudomonas aeruginosa
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1. Introduction
Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance
(MDR) and the complexity of the patients affected by these serious infections [1]. As new
antibiotic therapies come on the market, limited data exist on the effectiveness of such
treatments in clinical practice among varied clinical populations [2]. Aminoglycosides and
polymyxins have been used to treat MDR P. aeruginosa infections but present significant
toxicity profiles, including nephrotoxicity, ototoxicity, and neurotoxicity [3–5]. Additionally,
these agents are associated with suboptimal pharmacokinetics, narrow therapeutic index,
and inferior efficacy [4–7]. Historically, aminoglycosides and polymyxins have been used
to treat resistant P. aeruginosa infections. Still, clinical data defining optimal dosing and
combination regimens of these agents are lacking [2,8].
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P. aeruginosa resistance to aminoglycosides and polymyxins generally remains low
(<4% of MDR isolates). Therefore, the benefit–risk profile of these antibiotics pushes the
scale toward benefits outweighing risks in MDR and extensively resistant infections [9].
Alternatively, novel anti-pseudomonal antibiotics may be preferred if they result in at least
similar rates of positive clinical outcomes without the safety concerns. To date, there have
only been select comparative effectiveness studies comparing ceftolozane/tazobactambased regimens, a novel cephalosporin/beta-lactamase inhibitor combination, with aminoglycoside or polymyxin-based regimens, in patients with MDR P. aeruginosa infections [7,10].
Just one study in the United States has been conducted, including 100 ceftolozane/tazobactam
treated patients and 100 aminoglycoside or polymyxin-treated patients from 6 hospitals in
Michigan and Ohio [7]. This study found that acute kidney injury was significantly lower
in the ceftolozane/tazobactam group (adjusted odds ratio [aOR] 0.08; 95% confidence
interval [CI], 0.03–0.22), while no difference was observed in inpatient mortality (aOR
0.62, 95% CI 0.30–1.28). We, therefore, conducted a comparative effectiveness study of
ceftolozane/tazobactam versus aminoglycosides or polymyxins in another clinical population, patients treated in Veterans Affairs (VA) hospitals nationally, to assess the realworld benefit–risk profile of ceftolozane/tazobactam compared with aminoglycosides or
polymyxins for the treatment of MDR P. aeruginosa infections.
2. Results
We identified 23,176 hospitalized patients with positive P. aeruginosa cultures between January 2015 and April 2018 from 62 medical centers. After applying the inclusion/exclusion criteria shown in (Figure 1), we identified 212 patients with a MDR
P. aeruginosa infection, of which 26.9% (n = 57) were treated with ceftolozane/tazobactam,
and 73.1% (n = 155) were treated with aminoglycoside- or polymyxin-based regimens.
Of the 155 patients in the aminoglycoside or polymyxin treatment group, 132 received
aminoglycoside-based therapy (48 tobramycin, 50 amikacin, and 34 gentamicin) and 23 received polymyxin-based therapy (0 colistin, 23 polymyxin B).
Baseline demographics and clinical characteristics are presented in Table 1. Patients
treated with ceftolozane/tazobactam-based regimens were younger (mean age 67.5 vs. 71.1,
p = 0.03) and less likely to be of Hispanic or Latino ethnicity (1.8% vs. 22.6%, p < 0.001) than
patients treated with aminoglycoside- or polymyxin-based regimens. Those treated with
ceftolozane/tazobactam also had a higher comorbidity burden (median Charlson 5 vs. 3,
p = 0.01) as well as higher rates of spinal cord injury (38.6% vs. 21.9%, p = 0.02) and positive
P. aeruginosa cultures in the 30 days before admission (54.4% vs. 38.7%, p = 0.04) than
those treated with aminoglycoside- or polymyxin-based regimens. Patients treated with
ceftolozane/tazobactam were more likely to be admitted from a nursing home (12.3% vs.
3.2%, p = 0.02) and to have had a previous nursing home stay (5.3% vs. 0%, p = 0.02). There
were also significant differences in the P. aeruginosa culture source. A bone/joint source
of MDR P. aeruginosa was more common in those treated with ceftolozane/tazobactam
(12.3% vs. 0.7%, p < 0.001), and a urine source was less common (22.8% vs. 51.6%, p < 0.001).
Concomitant treatments were similar between treatment groups, except for meropenem
treatment (Table 2). Patients treated with ceftolozane/tazobactam-based regimens were
less likely to be treated with concomitant meropenem (15.8% vs. 30.3%, p = 0.03) than
those treated with aminoglycoside- or polymyxin-based regimens. Patients treated with
ceftolozane/tazobactam were more likely to be treated with meropenem (24.6% vs. 11.6%,
p = 0.02) and piperacillin/tazobactam (35.1% vs. 16.8%, p = 0.004) in the 30 days before the
treatment of interest than those treated with aminoglycoside- or polymyxin-based regimens.
The median time to initiation of the treatment of interest from MDR P. aeruginosa culture
collection was three days for both groups.
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Table 1. Baseline demographics and clinical characteristics of hospitalized patients with positive MDR
Pseudomonas aeruginosa infections with ceftolozane/tazobactam or aminoglycoside or polymyxin
treatment regimens.
Baseline Demographics and
Clinical Characteristics

Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/Polymyxins
(n = 155)

p-Value

Age, years
Mean (standard deviation)

67.5 (9.5)

71.1 (12.6)

0.03

Body mass index
Mean (standard deviation)

27.4 (7.0)

27.1 (7.3)

0.77

Male

55 (96.5%)

154 (99.4%)

0.18
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Table 1. Cont.
Baseline Demographics and
Clinical Characteristics

Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/Polymyxins
(n = 155)

p-Value

White

38 (66.7%)

109 (70.3%)

0.61

Hispanic or Latino

<5 (<8.8%)

35 (22.6%)

0.0003

Married

33 (57.9%)

63 (40.7%)

0.03

Admission source
Home/community
Hospital
Nursing home

24 (42.1%)
<5 (<8.8%)
7 (12.3%)

54 (34.8%)
12 (7.7%)
5 (3.2%)

0.33
0.76
0.02

Treating specialty
Medicine
Intensive care
Surgery
Other

19 (33.3%)
14 (24.6%)
11 (19.3%)
12 (21.1%)

66 (42.6%)
43 (27.7%)
12 (7.7%)
19 (12.3%)

0.22
0.64
0.02
0.11

Intensive care during admission

36 (63.2%)

89 (57.4%)

0.45

Surgery during admission

21 (36.8%)

57 (36.8%)

0.99

Charlson score
Median (interquartile range)

5 (3–7)

3 (2–6)

0.01

Elixhauser score
Median (interquartile range)

7 (4–10)

5 (3–8)

0.006

APACHE score
Median (interquartile range)

40 (29–52)

43 (33–57)

0.29

Primary diagnosis
Osteomyelitis
Pneumonia
Septicemia
Urinary tract infection
Other infections

<5 (<8.8%)
<5 (<8.8%)
16 (28.1%)
<5 (<8.8%)
<5 (<8.8%)

<5 (<3.2%)
5 (3.2%)
34 (21.9%)
12 (7.7%)
6 (3.9%)

0.38
0.44
0.35
0.76
0.19

50 (87.7%)
12 (21.1%)
7 (12.3%)
18 (31.6%)
30 (52.6%)
40 (70.2%)
13 (22.8%)

123 (79.4%)
13 (8.4%)
22 (14.2%)
28 (18.1%)
87 (56.1%)
98 (63.2%)
26 (16.8%)

0.16
0.01
0.72
0.03
0.65
0.35
0.31

23 (40.4%)
33 (57.9%)

72 (46.5%)
97 (62.6%)

0.43
0.53

34 (59.7%)
14 (24.6%)
32 (56.1%)
26 (45.6%)
25 (43.9%)

89 (57.4%)
30 (19.4%)
88 (56.8%)
55 (35.5%)
55 (35.5%)

0.77
0.41
0.93
0.18
0.26

18 (31.6%)
22 (38.6%)

30 (19.4%)
34 (21.9%)

0.06
0.02

<5 (<8.8%)
21 (36.8%)
10 (17.5%)
14 (24.6%)
25 (43.9%)

10 (6.5%)
38 (24.5%)
19 (12.3%)
43 (27.7%)
60 (38.7%)

0.52
0.08
0.32
0.64
0.49

27 (47.4%)
22 (38.6%)
11 (19.3%)
16 (28.1%)
8 (14.0%)

75 (48.4%)
47 (30.3%)
41 (26.5%)
47 (30.3%)
19 (12.3%)

0.89
0.25
0.28
0.75
0.73

Infection diagnosis
during admission
Bacterial Infection
Chronic osteomyelitis
Intraabdominal infection
Osteomyelitis
Pneumonia
Septicemia
Skin and Subcutaneous
infection
Ulcers
Urinary tract infection
Current medical problems
Respiratory failure
Fever of unknown origin
Acute renal failure
Shock
Complications of surgical
procedures or medical care
Osteomyelitis
Spinal cord injury
Medical history
Acute myocardial infarction
Congestive heart failure
Acute cerebrovascular disease
Cognitive disorders
Chronic obstructive
pulmonary disease
Diabetes without
complications
Diabetes with complications
Malignancy
Metastatic solid tumor
Spinal cord injury
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Table 1. Cont.
Baseline Demographics and
Clinical Characteristics

Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/Polymyxins
(n = 155)

p-Value

Healthcare exposures, 30 daysprior
to admission
Hospitalization
Nursing home
Intensive care
Surgery

17 (29.8%)
<5 (<8.8%)
<5 (<8.8%)
<5 (<8.8%)

36 (23.2%)
<5 (<3.2%)
6 (3.9%)
9 (5.8%)

0.33
0.02
0.70
1.00

Length of hospital stay, days
Median (interquartile range)

43 (16–80)

31 (13–107)

0.69

MDR P. aeruginosa culture source
Respiratory
Urine
Skin and tissue
Blood
Bone joint
Intra-abdominal
Other

21 (36.8%)
13 (22.8%)
10 (17.5%)
8 (14.0%)
7 (12.3%)
<5 (<8.8%)
5 (8.8%)

55 (35.5%)
80 (51.6%)
13 (8.4%)
14 (9.0%)
<5 (<3.2%)
<5 (<3.2%)
<5 (<3.2%)

0.85
0.0002
0.06
0.29
<0.0001
1.00
0.03

31 (54.4%)

60 (38.7%)

0.04

14 (24.6%)
10 (17.5%)
5 (8.8%)
6 (10.5%)
<5 (<8.8%)
<5 (<8.8%)
<5 (<8.8%)

35 (22.6%)
15 (9.7%)
6 (3.9%)
7 (4.5%)
<5 (<3.2%)
<5 (<3.2%)
<5 (<3.2%)

0.76
0.12
0.17
0.11
0.06
1.00
0.06

35 (61.4%)
53 (98.2%)
55 (96.5%)

82 (52.9%)
138 (91.4%)
138 (89.0%)

0.27
0.12
0.09

52 (91.2%)
35 (70.0%)

142 (91.6%)
120 (88.2%)

1.00
0.003

Previous positive P. aeruginosa
culture, prior 30 days
Culture source of prior positive P.
aeruginosa
Respiratory
Urine
Skin and tissue
Blood
Bone joint
Intra-abdominal
Other
Resistance
Aminoglycosides
Carbapenem
Extended-spectrum
cephalosporin
Fluoroquinolone
Piperacillin/tazobactam

Table 2. Treatment characteristics of hospitalized patients with positive MDR Pseudomonas aeruginosa
infections with ceftolozane/tazobactam or aminoglycoside or polymyxin treatment regimens.
Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/
Polymyxins (n = 155)

p-Value

Total number of changes in therapy during hospital admission
Median (interquartile range)

7 (3–14)

6 (3–15)

0.92

Time to study drug from initial antibiotics during hospital admission, days
Median (interquartile range)

13 (4–46)

9 (3–36)

0.27

Time to study drug from culture collection, days
Median (interquartile range)

3 (1–4)

3 (2–4)

0.93

Inpatient antimicrobial duration, days
Median (interquartile range)

34 (16–60)

23 (10–63)

0.18

Duration of study drug, days
Median (interquartile range)

12 (5–18)

7 (4–14)

0.005

Number of changes in therapy before the start of study drug
Median (interquartile range)

5 (1–10)

3 (1–8)

0.13

Number of days from hospital admission to start of study drug
Median (interquartile range)

14 (4–48)

11 (4–46)

0.36

Time to antipseudomonal antibiotics * from admission, days
Median (interquartile range)

0 (−2)

1 (0–6)

0.03

Any antibiotics, 30 days prior to the start of study drug

55 (96.5%)

144 (92.9%)

0.33

Treatment Characteristics
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Table 2. Cont.
Treatment Characteristics
Previous antibiotics, 30 days to 8 days prior to the start of study drug
Amikacin
Aztreonam
Cefepime
Ceftazidime
Cilastatin/imipenem
Ciprofloxacin
Daptomycin
Levofloxacin
Gentamicin
Meropenem
Piperacillin/tazobactam
Polymyxin B
Sulfamethoxazole/trimethoprim
Tobramycin
Vancomycin
Previous antibiotics class, 30 days to 8 days prior to the start of study drug
Aminoglycosides
Carbapenem
Extended-spectrum
cephalosporin
Fluoroquinolone
Piperacillin/tazobactam
Previous antibiotics, 7 days to 1 day prior to the start of study drug
Amikacin
Aztreonam
Cefepime
Ceftazidime
Cilastatin/imipenem
Ciprofloxacin
Colistin
Daptomycin
Levofloxacin
Gentamicin
Meropenem
Piperacillin/tazobactam
Polymyxin B
Sulfamethoxazole/trimethoprim
Tobramycin
Vancomycin
Previous antibiotics class, 7 days to 1 day prior to the start of study drug
Aminoglycosides
Carbapenem
Extended-spectrum
cephalosporin
Fluoroquinolone
Piperacillin/tazobactam
Concomitant antibiotics from start of study drug up to 15 days
Aztreonam
Cefepime
Ceftazidime
Imipenem
Ciprofloxacin
Daptomycin
Levofloxacin
Meropenem
Piperacillin/tazobactam
Sulfamethoxazole/trimethoprim

Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/
Polymyxins (n = 155)

p-Value

<5 (<8.8%)
<5 (<8.8%)
8 (14.0%)
<5 (<8.8%)
<5 (<8.8%)
10 (17.5%)
9 (15.8%)
9 (15.8%)
6 (10.5%)
14 (24.6%)
20 (35.1%)
<5 (<8.8%)
7 (12.3%)
<5 (<8.8%)
24 (42.1%)

5 (3.2%)
<5 (<3.2%)
20 (12.9%)
<5 (<8.8%)
8 (5.2%)
15 (9.7%)
8 (5.2%)
12 (7.7%)
5 (3.2%)
18 (11.6%)
26 (16.8%)
<5 (<3.2%)
9 (5.8%)
<5 (<3.2%)
53 (34.2%)

1.00
0.47
0.83
0.18
0.45
0.11
0.02
0.08
0.07
0.02
0.004
0.57
0.14
0.35
0.29

9 (15.8%)
15 (26.3%)
9 (15.8%)

13 (8.4%)
25 (16.1%)
21 (13.6%)

0.12
0.09
0.68

17 (29.8%)
20 (35.1%)

25 (16.1%)
26 (16.8%)

0.03
0.004

6 (10.5%)
<5 (<8.8%)
9 (15.8%)
6 (10.5%)
<5 (<8.8%)
5 (8.8%)
<5 (<8.8%)
7 (12.3%)
5 (8.8%)
<5 (<8.8%)
16 (28.1%)
19 (33.3%)
<5 (<8.8%)
<5 (<8.8%)
<5 (<8.8%)
27 (47.4%)

<5 (<3.2%)
<5 (<3.2%)
24 (15.5%)
<5 (<3.2%)
12 (7.7%)
12 (7.7%)
<5 (<3.2%)
8 (5.2%)
19 (12.3%)
<5 (<3.2%)
26 (16.8%)
38 (24.5%)
7 (4.5%)
7 (4.5%)
<5 (<3.2%)
72 (46.5%)

0.01
0.29
0.96
0.03
0.36
0.78
0.06
0.13
0.48
0.21
0.07
0.20
0.68
0.73
0.02
0.91

12 (21.1%)
18 (31.6%)
15 (26.3%)

8 (5.2%)
37 (23.9%)
28 (18.1%)

0.0004
0.26
0.18

10 (17.5%)
19 (33.3%)

30 (19.4%)
38 (24.5%)

0.75
0.20

<5 (<8.8%)
9 (15.8%)
<5 (<8.8%)
<5 (<8.8%)
<5 (<8.8%)
6 (10.5%)
<5 (<8.8%)
9 (15.8%)
14 (24.6%)
<5 (<8.8%)

5 (3.2%)
41 (26.5%)
10 (6.5%)
17 (11.0%)
13 (8.4%)
13 (8.4%)
18 (11.6%)
47 (30.3%)
42 (27.1%)
<5 (<3.2%)

1.00
0.10
1.00
0.09
0.36
0.63
0.07
0.03
0.71
0.39
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Table 2. Cont.
Treatment Characteristics
Concomitant antibiotics class, start of study drug up to 15 days
Carbapenem
Extended-spectrum
cephalosporin
Fluoroquinolone
Piperacillin/tazobactam

Ceftolozane/Tazobactam
(n = 57)

Aminoglycosides/
Polymyxins (n = 155)

p-Value

11 (19.3%)
11 (19.3%)

60 (38.7%)
47 (30.3%)

0.008
0.11

<5 (<8.8%)
14 (24.6%)

30 (19.4%)
42 (27.1%)

0.03
0.71

* Treatment with any one of the following antipseudomonal antibiotics: amikacin, aztreonam, cefepime,
ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, ciprofloxacin, colistin, doripenem, gentamicin,
imipenem, levofloxacin, meropenem, polymyxin B, piperacillin/tazobactam, tobramycin.

The overall inpatient mortality rate was 24.5% (52/212). After controlling for confounders, inpatient mortality was significantly lower in patients treated with ceftolozane/
tazobactam-based regimens than with aminoglycoside or polymyxin-based regimens
(15.8% vs. 27.7%, aOR 0.39, 95% CI 0.16–0.93; Table 3). No significant differences were
observed for any of the other clinical outcomes assessed, including acute kidney injury
(16.7% vs. 12.4%, aOR 0.86, 95% CI 0.32–2.33).
Table 3. Comparative effectiveness of ceftolozane/tazobactam compared with aminoglycoside
or polymyxin treatment regimens among hospitalized patients with positive MDR Pseudomonas
aeruginosa infections.
Outcomes

No. of Events/No. of Patients (%)
Ceftolozane/Aminoglycosides/
Tazobactam Polymyxins

Adjusted Odds Ratio 1
(95% Confidence Interval)

Inpatient mortality
Readmission within 30 days of discharge
Persistent positive culture 2
Microbiological clearance 3
Acute kidney injury 4

9/57 (15.8%)
12/48 (25.0%)
7/31 (22.6%)
13/42 (31.0%)
8/48 (16.7%)

0.39 (0.16–0.93) 5
0.87 (0.40–1.89) 6
0.38 (0.13–1.06) 7
0.88 (0.35–2.21) 8
0.86 (0.32–2.33) 9

43/155 (27.7%)
31/112 (27.7%)
39/93 (41.9%)
33/108 (30.6%)
16/129 (12.4%)

1

Stepwise logistic regression. 2 Positive culture of index infection organism after 7 days of treatment. Denominator
only includes patients with follow-up cultures. 3 Negative culture results at the site of index infection post index
treatment administration. Denominator only includes patients with follow-up cultures. 4 Acute kidney injury only
includes patients with baseline and follow-up serum creatinine. 5 Adjusted for prior positive P. aeruginosa culture,
surgical treating specialty, and meropenem administered 30 days to 8 days prior to the start of index treatment.
6 No additional variables in the adjusted model. 7 Adjusted for prior positive P. aeruginosa culture. 8 Adjusted for
P. aeruginosa culture site urine, marital status, and history of inflammation. 9 Adjusted for P. aeruginosa culture site
urine and Charlson score.

3. Discussion
In hospitalized patients with MDR P. aeruginosa infections, we found a significantly
lower risk of in-hospital mortality among patients treated with ceftolozane/tazobactambased regimens compared with those treated with aminoglycoside- or polymyxin-based
regimens in the national VA Healthcare system. We did not observe differences in 30-day
readmission, persistent positive culture, microbiological clearance, or acute kidney injury.
Our national study population had important similarities and differences from the
previous comparative effectiveness study conducted in the United States [7]. Our study
population was older (mean age 70 years), more male (99%), and more white (69%) than
previous work (mean age 59 years, 68% male, and 58% white). In both studies, most
patients presented from home (37% of our study vs. 39% previous work), and chronic
pulmonary disease, diabetes, and congestive heart failure were common comorbidities.
However, the median Charlson Comorbidity Index was higher in our study (4) than in
previous work (3) [7]. Most patients in the previous study were admitted to the ICU (69%),
and the most common infection type was ventilator-associated pneumonia (52%), with
46% of patients with sepsis. A total of 59% of our patients received intensive care during
admission, with only 3.8% and 24% of our patients being diagnosed with pneumonia and
sepsis, respectively. Based on culture data, only 36% of our patients had a pseudomonal
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respiratory tract infection. Patients with pneumonia generally have worse outcomes,
and pneumonia is an independent risk factor for death in patients with pseudomonal
infections [11,12]. Therefore, patients in previous work may have been more severely ill,
leading to differences in the study findings. Interestingly, however, inpatient mortality
rates were similar in both studies (25% of our study vs. 23% in previous work) [7].
Additionally, there was higher concomitant antibiotic therapy in both treatment groups
in our study compared to previous work, with 96% in the ceftolozane/tazobactam and
94% in the aminoglycoside- or polymyxin-based treatment group having received concomitant antibiotic therapy in our study, as compared to 15% in the ceftolozane/tazobactam
and 72% in the aminoglycoside or polymyxin treatment group in previous work [7]. Importantly, we assessed differences between the treatment groups in concomitant therapy
from the index date (initiation of ceftolozane/tazobactam or aminoglycosides/polymyxins)
through 15 days after the index date, while previous work only considered combination
therapy with secondary agents also targeting P. aeruginosa for >48 h. Moreover, unlike
our study, the previous study did not consider differences in treatments leading up to the
index date, including previous antibiotics for past infections and empiric therapy for the
treatment of the MDR P. aeruginosa infection. These important differences in treatment
may have impacted the therapy chosen (ceftolozane/tazobactam vs. aminoglycoside or
polymyxin-based regimens) and clinical outcomes.
We found no difference in clinical outcomes assessed except inpatient mortality. In previous work, receipt of ceftolozane/tazobactam was associated with increased clinical cure
(aOR 2.63; 95% confidence interval [CI], 1.31–5.30) and decreased acute kidney injury
(AKI, aOR, 0.08; 95% CI, 0.03–0.22) [7]. We did not assess clinical cure. Clinical cure is
a subjective clinical outcome defined as improvement in symptoms. However, improvement in symptoms can occur from administering non-antibiotic medications (e.g., fever
reducing, anti-inflammatory, steroids). Further, clinical cure may be defined differently
between clinicians and investigators [7,13]. Another small, matched case-control study
which included 48 patients from 9 medical centers in Italy with nosocomial pneumonia
or bloodstream infection due to MDR or extensively drug-resistant P. aeruginosa found
no difference in clinical cure (13% vs. 18%, p = 0.11) and decreased acute kidney injury
(0 vs. 8%, p = 0.04) among those treated with ceftolozane/tazobactam versus colistin- or
aminoglycoside-based regimens [10]. We did not find any difference in acute kidney injury
in our study (aOR, 0.86; 95% CI, 0.32–2.33).
In both the American comparative effectiveness study and the Italian case-control study,
similar survival rates were observed among those treated with ceftolozane/tazobactam
versus aminoglycoside- or polymyxin-based regimens [7,10]. However, the previous study
of patients in the United States may have detected a difference had they had a larger
sample size (at least 250 per group) assuming a crude incidence of in-hospital mortality
of 20% vs. 25% and an aOR of 0.62. Previous work among patients in Italian medical
centers was also likely underpowered to detect a survival benefit [10]. We observed a
benefit in in-hospital survival with ceftolozane/tazobactam. Consistent with our findings,
a single-center case-control study among 57 patients with hematologic malignancy and
P. aeruginosa infection, 50.9% due to MDR and 29.8% to extensively drug-resistant strains,
demonstrated a survival benefit associated with ceftolozane/tazobactam [14]. In this singlecenter case-control study, the 30-day mortality rate was lower among patients treated with
ceftolozane/tazobactam versus standard of care antibiotics (5.3% vs. 28.9%; p = 0.045) [14].
Among those with known MDR P. aeruginosa infections, our results and previous
work suggest that treatment with ceftolozane/tazobactam may better meet antimicrobial stewardship goals to optimize outcomes and minimize unintended consequences
of aminoglycoside- or polymyxin-based treatment, when the isolates are ceftolozane/
tazobactam-susceptible [15]. Our results build on previous findings that in patients with
serious infections due to MDR P. aeruginosa, ceftolozane/tazobactam has been associated
with higher rates of clinical cure and lower rates of nephrotoxicity than aminoglycosideor polymyxin-based treatment, and ceftolozane/tazobactam may also be associated with
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an inpatient survival benefit [7,10]. As such, our results support previous studies which
have concluded that ceftolozane/tazobactam may be preferred over aminoglycoside- or
polymyxin-based treatment for MDR P. aeruginosa infections, especially in patients who
may be at higher risk for aminoglycoside or nephrotoxicity, including those who are older
and those with underlying comorbidities and illness [3,15]. Moreover, early treatment with
ceftolozane/tazobactam may be prudent once susceptibly is known, as previous work has
found that starting ceftolozane/tazobactam less than four days after the positive culture is
associated with higher clinical and microbiological cure rates [12].
The main limitation to this work is that we were unable to distinguish between actual
MDR P. aeruginosa infection and colonization. Only 23.6% of patients had a primary
diagnosis of septicemia during admission, and the percentage with primary diagnoses
of other infections assessed was only ~<5%. However, when diagnoses were considered
anytime during admission, 82% had a diagnosis of an unspecified bacterial infection,
65% had septicemia, and 55% had pneumonia. However, all patients were treated with
at least 48 h of ceftolozane/tazobactam, aminoglycosides, or polymyxins, and all MDR
P. aeruginosa isolates were susceptible to the treatment of interest.
Another limitation is that we did not assess the dosages or blood levels of study
medications and cannot determine whether study drugs were appropriately dosed. Dosing
strategies for aminoglycosides and polymyxins vary and optimal dosing targets are debated,
resulting in potential overdosing or underdosing with aminoglycosides and polymyxins,
as opposed to ceftolozane/tazobactam, which is generally dosed at 1.5 or 3 g every 8 h with
normal renal function [7,16]. We also did not capture alternative routes of administration
of the study drugs, such as via nebulization.
We used a broad definition of previous and concomitant concurrent antibiotic treatments to control for all antibiotics used in addition to the treatment of interest. However,
since we assessed all antibiotic exposures, it is possible that some of the antibiotic exposures
were not solely for the treatment of the MDR P. aeruginosa infection. Ceftazidime/avibactam
is another novel cephalosporin-beta-lactamase inhibitor therapy used for MDR P. aeruginosa
infections that was approved in 2018; however, we did not include patients treated with
ceftazidime/avibactam in our study. Due to their approvals after our study time frame,
we also did not evaluate other more recently approved antibiotics, such as plazomicin,
cefiderocol, and imipenem-cilastatin-relebactam [2].
Channeling bias may have influenced our study findings, as rates of acute kidney
injury did not vary between the treatment groups. Patients at higher risk for acute kidney
injury may have been preferentially treated with ceftolozane/tazobactam. The generalizability of this study may be limited to older male patients as this study was conducted
among patients admitted to VA hospitals. Another limitation is that we assessed all-cause
mortality and cannot rule out the impact of underlying conditions on mortality in our older,
more clinically complex study population.
4. Materials and Methods
This comparative effectiveness analysis included hospitalized VA patients with positive P. aeruginosa cultures between January 2015 and April 2018. Figure 1 presents a flow
chart for the study of cohort identification. Multi-drug resistance was defined as any
isolate that tested either intermediate (I) or resistant (R) to at least one antibiotic in at
least three of these categories: extended-spectrum cephalosporins (cefepime, ceftazidime),
fluoroquinolones (ciprofloxacin, levofloxacin), aminoglycosides (amikacin, gentamicin, tobramycin), carbapenems (imipenem, meropenem, doripenem), and piperacillin (piperacillin,
piperacillin/tazobactam). We then included patients (1) treated with ceftolozane/tazobactam
or aminoglycosides or polymyxins for ≥48 h without overlapping ceftolozane/tazobactam
and aminoglycoside or polymyxin therapy for >48 h, (2) with MDR P. aeruginosa isolates
susceptible to the treatment of interest (ceftolozane/tazobactam; or aminoglycoside or
polymyxin-based regimens), and (3) treatment initiated one day prior through 5 days after
culture collection. The index date was defined as the start date of the treatment of interest.

Antibiotics 2022, 11, 626

10 of 11

We assessed the following objective clinical outcomes: inpatient mortality, 30-day
readmission from discharge, persistent positive culture (defined as at least one subsequent
positive culture after starting the treatment of interest, with and having received at least
seven days of any antibiotic therapy), microbiological clearance (defined as a negative
follow-up culture among those with follow-up cultures), and acute kidney injury (defined
as a serum creatinine increase of 1.5 times the baseline serum creatinine).
We assessed several covariates, including demographics, clinical characteristics, current medical problems, medical history, infection diagnoses, culture source, resistance of
the MDR P. aeruginosa isolate, and concomitant antibiotic treatment (Table 1). All antibiotic
therapies received from the admission date until the index date were also evaluated. Concomitant treatments were defined as any antibiotic received from the index date through
15 days after initiation of the treatment of interest.
Baseline characteristics of patients in the ceftolozane/tazobactam and aminoglycosideor polymyxin-based treatment groups were compared using the chi-square, Fisher’s exact
test, t-test, or non-parametric Wilcoxon test, as appropriate. Confounding was assessed
by controlling for variables significantly associated with the treatment of interest and the
clinical outcome. Variables were included in the initial model if the univariate likelihood
ratio p-value was ≤0.10 and were retained in the final model if the p-value was <0.05.
aOR and 95% confidence intervals (CI) were calculated using automatic stepwise logistic
regression. Different models were developed for each clinical outcome, each controlling for
identified confounders of the specific exposure–outcome relationship.
5. Conclusions
In hospitalized patients with MDR P. aeruginosa, the risk of inpatient mortality was
61% lower among patients treated with ceftolozane/tazobactam compared with those
treated with aminoglycoside or polymyxin-based regimens. Readmission, persistent positive cultures, microbiological clearance, and acute kidney injury did not differ between the
treatment groups. Ceftolozane/tazobactam may be a treatment alternative to aminoglycosides or polymyxins for MDR P. aeruginosa infections, as it may have a more favorable
safety profile and may be associated with improved clinical outcomes.
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